busulfan has been researched along with Lymphopenia in 2 studies
Lymphopenia: Reduction in the number of lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Prophylactic T cell depletion via antithymocyte globulin (ATG) during ASCT conditioning is one of the standards of care for GVHD prophylaxis, although the optimal dosing strategy is still unclear." | 5.56 | Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. ( Bene, MC; Blin, N; Chevallier, P; Debord, C; Dubruille, V; Duquesne, A; Eveillard, M; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Bris, Y; Le Gouill, S; Mahe, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Wuilleme, S, 2020) |
| " Prophylactic T cell depletion via antithymocyte globulin (ATG) during ASCT conditioning is one of the standards of care for GVHD prophylaxis, although the optimal dosing strategy is still unclear." | 1.56 | Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. ( Bene, MC; Blin, N; Chevallier, P; Debord, C; Dubruille, V; Duquesne, A; Eveillard, M; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Bris, Y; Le Gouill, S; Mahe, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Wuilleme, S, 2020) |
| "Lymphopenia was also a significant prognostic factor for progression-free survival (HR 3." | 1.43 | A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. ( Cheong, JW; Cho, H; Chung, H; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Kim, YR; Lee, JY; Min, YH; Park, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jullien, M | 1 |
| Guillaume, T | 1 |
| Peterlin, P | 1 |
| Garnier, A | 1 |
| Le Bourgeois, A | 1 |
| Debord, C | 1 |
| Mahe, B | 1 |
| Dubruille, V | 1 |
| Wuilleme, S | 1 |
| Blin, N | 1 |
| Touzeau, C | 1 |
| Gastinne, T | 1 |
| Tessoulin, B | 1 |
| Le Bris, Y | 1 |
| Eveillard, M | 1 |
| Duquesne, A | 1 |
| Moreau, P | 1 |
| Le Gouill, S | 1 |
| Bene, MC | 1 |
| Chevallier, P | 1 |
| Jang, JE | 1 |
| Kim, YR | 1 |
| Kim, SJ | 1 |
| Cho, H | 1 |
| Chung, H | 1 |
| Lee, JY | 1 |
| Park, H | 1 |
| Kim, Y | 1 |
| Cheong, JW | 1 |
| Min, YH | 1 |
| Kim, JS | 1 |
2 other studies available for busulfan and Lymphopenia
| Article | Year |
|---|---|
Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft.
Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Hos | 2020 |
A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2016 |